Published in J Pharmacol Exp Ther on September 01, 1983
Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol (2010) 1.93
Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav (2004) 1.86
Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res (2002) 1.84
Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist. Neuropsychopharmacology (2004) 1.65
Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist. Neuropsychopharmacology (2005) 1.55
Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov (2009) 1.30
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl) (2003) 1.28
Characterization of susceptibility to audiogenic seizures in ethanol-dependent rats after microinjection of gamma-aminobutyric acid (GABA) agonists into the inferior colliculus, substantia nigra or medial septum. J Pharmacol Exp Ther (1983) 1.17
Synaptic effects induced by alcohol. Curr Top Behav Neurosci (2013) 1.13
Repeated lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced anxiety-like behavior. Neuropsychopharmacology (2007) 1.08
Similar anxiety-like responses in male and female rats exposed to repeated withdrawals from ethanol. Pharmacol Biochem Behav (2004) 1.03
Modulation of ethanol withdrawal-induced anxiety-like behavior during later withdrawals by treatment of early withdrawals with benzodiazepine/gamma-aminobutyric acid ligands. Alcohol Clin Exp Res (2005) 1.01
Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology (Berl) (2006) 1.00
Brain regional differences in the effect of ethanol on GABA release from presynaptic terminals. J Pharmacol Exp Ther (2008) 0.95
Pharmacological modulation of repeated ethanol withdrawal-induced anxiety-like behavior differs in alcohol-preferring P and Sprague-Dawley rats. Pharmacol Biochem Behav (2005) 0.90
Similar effects of ethanol and flumazenil on acquisition of a shuttle-box avoidance response during withdrawal from chronic ethanol treatment. Br J Pharmacol (1993) 0.86
The Interplay between the Hippocampus and Amygdala in Regulating Aberrant Hippocampal Neurogenesis during Protracted Abstinence from Alcohol Dependence. Front Psychiatry (2013) 0.84
The Impact of Caffeine on the Behavioral Effects of Ethanol Related to Abuse and Addiction: A Review of Animal Studies. J Caffeine Res (2013) 0.82
Administration of neurotoxic doses of MDMA reduces sensitivity to ethanol and increases GAT-1 immunoreactivity in mice striatum. Psychopharmacology (Berl) (2009) 0.77
Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment. Alcohol Res Health (2010) 0.76
Synaptic targets: Chronic alcohol actions. Neuropharmacology (2017) 0.75
Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990. Br J Pharmacol (1990) 0.75
Changes in intrinsic inhibition in isolated hippocampal slices during ethanol withdrawal; lack of correlation with withdrawal hyperexcitability. Br J Pharmacol (1992) 0.75
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Selective release of newly synthesized norepinephrine from the cat spleen during sympathetic nerve stimulation. J Pharmacol Exp Ther (1968) 1.99
Metabolism of normetanephrine-H3 in rat brain--identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol (1968) 1.86
Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol (1997) 1.73
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther (2013) 1.73
Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther (1970) 1.69
3-methoxy-4-hydroxyphenylglycol sulfate in brain and cerebrospinal fluid. Biochem Pharmacol (1968) 1.64
Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A (1991) 1.38
Silver spoons: supervised volunteers provide feeding of patients. Geriatr Nurs (1997) 1.37
Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther (2001) 1.37
Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther (1983) 1.36
Metabolism of tyramine-3H and octopamine-3H by rat brain. Biochem Pharmacol (1969) 1.35
Effects of thyrotropin-releasing hormone in depression. Lancet (1972) 1.34
Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol (2000) 1.32
Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A (1996) 1.32
Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol (1971) 1.31
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Multiple withdrawals from chronic ethanol "kindles" inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol Clin Exp Res (1990) 1.30
Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol Clin Exp Res (1998) 1.28
Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther (1981) 1.26
Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res (1996) 1.24
Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology (Berl) (1997) 1.24
Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther (1987) 1.19
Sensitivity to ethanol across development in rats: comparison to [3H]zolpidem binding. Alcohol Clin Exp Res (1998) 1.17
Effect of central catecholamine alterations on the hypothermic response to 6-hydroxydopamine in desipramine treated rats. Br J Pharmacol (1971) 1.17
Characterization of susceptibility to audiogenic seizures in ethanol-dependent rats after microinjection of gamma-aminobutyric acid (GABA) agonists into the inferior colliculus, substantia nigra or medial septum. J Pharmacol Exp Ther (1983) 1.17
Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci (1993) 1.16
Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br J Pharmacol (1972) 1.14
Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity. Psychopharmacologia (1974) 1.10
Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther (1998) 1.09
Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine. J Pharmacol Exp Ther (1973) 1.09
Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil. Psychopharmacology (Berl) (2000) 1.08
Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther (1984) 1.07
Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther (2007) 1.05
The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome. Neurosci Biobehav Rev (1985) 1.05
Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev (2001) 1.03
Preparative methods for brain slices: a discussion. J Neurosci Methods (1995) 1.01
Regional specificity of ethanol and NMDA action in brain revealed with FOS-like immunohistochemistry and differential routes of drug administration. Alcohol Clin Exp Res (2001) 1.01
6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther (1987) 1.01
Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience (1994) 1.01
Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem (1999) 1.00
GABAergic modulation of ethanol-induced motor impairment. J Pharmacol Exp Ther (1982) 0.98
Supersensitivity to the respiratory stimulatory effect of TRH in 5,7-dihydroxytryptamine-treated rats. Brain Res (1984) 0.97
Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther (1975) 0.97
Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res (1998) 0.97
Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry (1982) 0.96
Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res (1997) 0.96
Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther (1996) 0.95
Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr (1981) 0.95
Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem (1981) 0.94
The neuropharmacology of respiratory control. Pharmacol Rev (1982) 0.93
Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther (1979) 0.92
Alteration of avoidance and ingestive behavior after destruction of central catecholamine pathways with 6-hydroxydopamine. Pharmacol Biochem Behav (1975) 0.92
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J Pharmacol Exp Ther (1969) 0.92
Comparison of the CNS effects induced by TRH and bicuculline after microinjection into medial septum, substantia nigra and inferior colliculus: absence of support for a GABA antagonist action for TRH. Pharmacol Biochem Behav (1984) 0.92
Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD. Science (1967) 0.92
Molecular basis for regionally specific action of ethanol on gamma-aminobutyric acidA receptors: generalization to other ligand-gated ion channels. J Pharmacol Exp Ther (1993) 0.92
Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol (1974) 0.92
Acute tolerance to ethanol inhibition of NMDA-mediated EPSPs in the CA1 region of the rat hippocampus. Brain Res (1994) 0.92
Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry (1982) 0.92
Thydrotropin releasing hormone: antagonism of pentobarbital in rodents. Life Sci (1974) 0.91
Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry (1967) 0.91
Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine. J Pharmacol Exp Ther (1973) 0.91
Site-specific enhancement of gamma-aminobutyric acid-mediated inhibition of neural activity by ethanol in the rat medial septal area. J Pharmacol Exp Ther (1990) 0.91
Evidence for site specific ethanol actions in the CNS. Alcohol Drug Res (1986) 0.91
Distribution of [3H]zolpidem binding sites in relation to messenger RNA encoding the alpha 1, beta 2 and gamma 2 subunits of GABAA receptors in rat brain. Neuroscience (1995) 0.90
Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards. J Chromatogr (1985) 0.90
Evaluation of the effects of nerve growth factor and anti-nerve growth factor on the development of central catecholamine-containing neurons. Brain Res (1978) 0.90
The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. Gene Ther (2011) 0.90
Beta-adrenergic receptor distribution in human and rat hippocampal formation: marked species differences. Brain Res (1991) 0.90
Investigations into the mechanism of reduction of ethanol sleep by thyrotropin-releasing hormone (TRH). J Pharmacol Exp Ther (1976) 0.89
An evaluation of the locomotor stimulating action of ethanol in rats and mice. Psychopharmacology (Berl) (1981) 0.89
Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J Pharmacol Exp Ther (1985) 0.88
Ethanol inhibits NMDA-evoked electrophysiological activity in vivo. J Pharmacol Exp Ther (1991) 0.88
Electrically elicited seizures from the inferior colliculus: a potential site for the genesis of epilepsy? Exp Neurol (1984) 0.88
Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J Pharmacol Exp Ther (1983) 0.88
Behavioral and biochemical interactions of 5,7-dihydroxytryptamine with various drugs when administered intracisternally to adult and developing rats. Brain Res (1975) 0.88
Electrophysiological evidence that ethanol alters function of medial septal area without affecting lateral septal function. J Pharmacol Exp Ther (1990) 0.88
Alterations in consummatory behavior following intracisternal injection of 6-hydroxydopamine. Pharmacol Biochem Behav (1974) 0.88
Effects of thyrotropin-releasing hormone on locomotor activity, operant performance and ingestive behavior. J Pharmacol Exp Ther (1979) 0.87
Antagonism of ethanol narcosis by thyrotropin releasing hormone. Life Sci (1974) 0.87